Withdrawing interferon-α from psychiatric patients: clinical care or unjustifiable stigma?

A. Spennati and C. M. Pariante*

Institute of Psychiatry, King’s College London, Department of Psychological Medicine, London, UK

IFN-α is an effective therapy for chronic viral hepatitis C and today still represents an effective first-line treatment. Unfortunately, its use is associated with a number of side-effects, including psychiatric problems like depression, mania, psychosis, delirium and other cognitive disturbances. Clinicians have been concerned about the risks of worsening of pre-existent psychiatric disorders and of precipitating suicidal attempts in psychiatric patients. The presence of a mental illness is, therefore, often deemed to be a contraindication to the use of antiviral treatment. However, this amounts to stigmatization and discrimination, as it basically implies withholding a life-saving medical treatment because of a psychiatric diagnosis. Is this clinically and socially acceptable? With novel treatments now entering clinical practice as adjuvant to IFN-α, it is particularly important to make a statement now, to ensure that psychiatric patients are not left behind. The aim of this editorial is to critically discuss this notion, by reviewing the few studies (n = 14) that have indeed administered IFN-α to patients with a pre-existing psychiatric disorder. We find evidence that these patients have rates of treatment adherence and sustained virological response similar to those of non-psychiatric patients, and that their IFN-α-induced psychiatric symptoms respond successfully to clinical management. We conclude that there is no support to withdrawing IFN-α therapy from psychiatric patients.

Received 21 February 2012; Revised 12 July 2012; Accepted 17 July 2012; First published online 14 September 2012

Key words: Cytokines, depression, hepatitis C, immune, inflammation, interferon-α, stigma.

Introduction

Hepatitis C virus (HCV) infection is a major health problem affecting approximately 170 million people worldwide and 4 million of people in the USA (Asnis & De La Garza, 2006). Up to 85% of HCV-infected individuals may develop chronic hepatitis C, a disease associated with serious clinical complications, including cirrhosis of the liver and hepatocellular carcinoma. Chronic hepatitis C is the leading cause of liver transplantation in the developed world. It is estimated that there are approximately 5 million carriers of HCV in Europe, 70–80% of whom are likely to develop a chronic infection. In the UK, around 216,000 individuals are chronically infected with hepatitis C; and, as in all countries, the major risk factor for infection is injecting drug use (HPA, 2011). Therefore, it is easy to understand the importance of using appropriate antiviral treatments to successfully induce a viral remission, in order to reduce the morbidity and mortality associated with chronic hepatitis C.

First-line treatment consists of a combination therapy with pegylated IFN-α (pegIFN-α) plus ribavirin. In pegIFN-α, polyethylene glycol is added to make IFN-α’s half-life longer, thus allowing once-weekly administration. This combination therapy can reach a sustained viral eradication in 45–95% of patients, according to viral genotype, viral load and treatment adherence. Novel protease inhibitor antiviral drugs will soon enter clinical care, and promise to increase considerably the rate of viral eradication; but they will be added to IFN-α – not be a substitute for it.

IFN-α neuropsychiatric side-effects

Unfortunately, the use of IFN-α is associated with numerous side-effects, both medical and neuropsychiatric. Among the first, there are flu-like symptoms, including fever, chills, malaise, tachycardia, headache, arthralgias and myalgias, occurring in more than 30% of patients, usually at the beginning of the therapy. Neuropsychiatric side-effects are also common, and there are reports of a variety of symptoms, including depressive syndromes, manic and psychotic episodes, and delirium. In a previous review (Quelhas & Lopes, 2009), prospective studies (that excluded patients with a lifetime history of psychiatric disorders) report an incidence of IFN-α-induced...
Table 1. Summary of studies on psychiatric patients taking interferon-α

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Diagnosis</th>
<th>IFN-α dose</th>
<th>Outcome of therapy with IFN-α</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dieperink et al. 2003</td>
<td>55 patients with hepatitis, of which 42 treated with IFN-α. Prospective study</td>
<td>11 patients with psychiatric diagnosis</td>
<td>3 MU of IFN-α three times/week and ribavirin 1000–1200 mg/day for 24 weeks</td>
<td>Patients with psychiatric diagnosis scored higher on all rating scales at baseline and became more symptomatic during treatment. Of the 31 (74%) patients not in psychiatric care at baseline, 15 (48%) required treatment for neuropsychiatric symptoms, and 7 (23%) met criteria for major depression during INF therapy. The control group of 13 untreated subjects showed little change over the 24-week period.</td>
</tr>
<tr>
<td>Dieperink et al. 2008</td>
<td>16 Prospective study</td>
<td>16 patients with PTSD, 5 received IFN, 11 did not receive treatment</td>
<td>1.5 μg/kg pegIFN-α-2b once a week plus ribavirin, for 12 or 24 weeks.</td>
<td>Depressive scores significantly increased among the 5 patients treated with IFN, but no significant differences in PTSD scores were found compared with 11 control patients.</td>
</tr>
<tr>
<td>Eon et al. 2009</td>
<td>394 Prospective study</td>
<td>47 patients with depression according to CES-D</td>
<td>Combination of pegIFN-α and ribavirin</td>
<td>Patients with pre-existent depression were more likely to have psychiatric adverse events or start new antidepressants (45% vs 28%) and to have had early treatment discontinuation (38% vs 13%) Sustained virological response rates were similar (38% vs 40%) to those of participants without baseline depression.</td>
</tr>
<tr>
<td>Ho et al. 2001</td>
<td>33 Retrospective study</td>
<td>19 patients with previous psychiatric diagnosis</td>
<td>5 MU of IFN-α three times/week for 6 months, followed by a tapering dose for additional 6 months</td>
<td>Of the patients with pre-existing psychiatric diagnoses, 13/19 (68%) developed major adverse events requiring intervention or discontinuation of therapy. 4/14 (29%) patients without psychiatric diagnoses developed major adverse events. In the psychiatric group, 6/19 (32%) developed major neuropsychiatric side-effects compared to 2/14 patients (14%) in the non-psychiatric group. Patients with and without psychiatric diagnoses had equivalent virological responses to therapy.</td>
</tr>
<tr>
<td>Huckans et al. 2010</td>
<td>60 Retrospective chart review</td>
<td>30 patients with schizophrenia, 30 controls</td>
<td>PegIFN-α-2a or -2b or non-pegIFN for 24 or 48 weeks</td>
<td>For all genotypes considered, the patients with schizophrenia were not more likely than controls to discontinue therapy early for psychiatric symptoms. Patients with schizophrenia seemed to be able to complete and respond to antiviral therapy for chronic hepatitis C at rates comparable to those of controls. Strict adherence was similar in psychiatric and non-psychiatric patients (35% v. 39%) as was the rate of sustained virological response (52% v. 51%). The rate of mental adverse events was higher in psychiatric patients (78% v. 57%).</td>
</tr>
<tr>
<td>Lang et al. 2010</td>
<td>1860 Cohort study</td>
<td>403 patients with pre-existing psychiatric disorders</td>
<td>Combination of pegIFN-α and ribavirin</td>
<td>41 (30%) of the control patients had adverse psychiatric events. Psychiatric events occurred in 8 (36%) of 22 patients with positive PHQ but negative MDQ; 8 (73%) of 11 with positive PHQ and positive MDQ had psychiatric adverse events The overall sustained viral response rate was 58% and not statistically significant among groups.</td>
</tr>
<tr>
<td>Lim et al. 2010</td>
<td>165 Retrospective study</td>
<td>33 patients with positive PHQ-9 for mood disorders, 132 controls with negative PHQ</td>
<td>Combination of pegIFN-α and ribavirin</td>
<td>No significant rise in psychiatric symptoms among patients on IFN-α compared to baseline. A lifetime history of major depression did not predict the onset or worsening of mood symptoms, although such patients had higher mean depression scores throughout their treatment. None of the patients made a suicidal attempt.</td>
</tr>
<tr>
<td>Mulder et al. 2000</td>
<td>63 Prospective study</td>
<td>47% of total patients with pre-existing major depression</td>
<td>3 MU of IFN-α, three times a week for 6 months.</td>
<td>No significant rise in psychiatric symptoms among patients on IFN-α compared to baseline. A lifetime history of major depression did not predict the onset or worsening of mood symptoms, although such patients had higher mean depression scores throughout their treatment. None of the patients made a suicidal attempt.</td>
</tr>
<tr>
<td>Author</td>
<td>Year</td>
<td>Study Design</td>
<td>Participants</td>
<td>Intervention</td>
</tr>
<tr>
<td>--------</td>
<td>------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Pariante et al. 1999</td>
<td>50</td>
<td>Prospective</td>
<td>16 patients with current psychiatric diagnosis</td>
<td>6-10 MU of IFN-α, three times a week for 12 months</td>
</tr>
<tr>
<td>Pariante et al. 2002</td>
<td>60</td>
<td>Prospective</td>
<td>25 patients with psychiatric diagnosis, 35 controls</td>
<td>6-10 MU of IFN-α three times a week for 12 months</td>
</tr>
<tr>
<td>Schaefer et al. 2003</td>
<td>81</td>
<td>Prospective</td>
<td>16 patients with psychiatric disorders, 21 on methadone substitution treatment, 21 former drug users, 23 controls</td>
<td>3 MU of IFN-α-2a three times weekly plus ribavirin</td>
</tr>
<tr>
<td>Schaefer et al. 2005</td>
<td>36</td>
<td>Prospective, open label study</td>
<td>14 patients with psychiatric illness (group A) treated with citalopram, 11 patients with psychiatric illness, not treated with antidepressant (group B), 11 patients with no psychiatric illness (group C)</td>
<td>PegIFN-α-2b plus ribavirin for 24 weeks</td>
</tr>
<tr>
<td>Schaefer et al. 2007</td>
<td>70</td>
<td>Prospective</td>
<td>22 patients with psychiatric diagnosis (10 with affective disorder, 6 schizophrenia, 6 personality disorder), 17 controls, 18 methadone substitution treatment, 13 former drug users</td>
<td>IFN-α-2b (1.5 µg/kg a week) or IFN-α-2a (180 µg/week) plus ribavirin for 24 or 48 weeks</td>
</tr>
<tr>
<td>Van Thiel et al. 1995</td>
<td>31</td>
<td>Prospective, open label study</td>
<td>31 patients with chronic HCV and psychiatric illness</td>
<td>5 MU of IFN-α, three times/week for 6 months (n = 17) or 5 MU daily for 6 months (n = 14)</td>
</tr>
</tbody>
</table>

CESD, Center for Epidemiologic Studies Depression Scale; IFN, interferon; PHQ, Physician Health Questionnaire; PTSD, post-traumatic stress disorder; MDQ, Mood Disorders Questionnaire; MU, million units.
neuropsychiatric symptoms of 12–41%, while studies without this exclusion criterion report an incidence of 17–58%. Depression appears to be the most common side-effect in patients with chronic hepatitis C, and the incidence of major depressive episodes (MDEs), diagnosed according to DSM-IV-TR criteria, generally ranges from 12% to 42% (Quelhas & Lopes, 2009). The incidence of mania during IFN-α treatment is unknown; however, several cases have been reported, including cases of mania emerging spontaneously after IFN-α-induced depression and/or after withdrawal of IFN-α, and reports of ‘switches’ from depression to mania during antidepressant therapy (Quelhas & Lopes, 2009). Cognitive side-effects, especially memory disturbances and concentration problems, have also been found in 10–20% of patients receiving IFN-α, with the risk of cognitive decline possibly being higher with a larger cumulative dose of IFN-α and a longer duration of treatment. There are a few case reports of psychotic episodes induced by IFN-α therapy (Quelhas & Lopes, 2009).

Worsening of psychiatric symptoms in IFN-α therapy

Generally, patients with chronic hepatitis C tend to have a significant history of psychopathology (Yovtcheva et al. 2001), which has been considered by some authors as a significant cause for treatment withdrawal, due to the theoretical risk of worsening of psychiatric symptomatology induced by IFN-α treatment. In particular, concerns have been raised about worsening or exacerbation of depression or suicidal ideation, as well as of psychotic symptoms in patients suffering from bipolar disorder and psychotic illnesses. As recently as in the 2012 Recommendations from the USA National Hepatitis C Program Office, it is prescribed that ‘uncontrolled depression or active suicidal ideation is an absolute contraindication to IFN-based therapies’ (Yee et al. 2012). While we agree with the accepted clinical practice that patients with active psychopathology should be assessed and supported before starting IFN-α, the wording of the recommendation undoubtedly confirms the degree of anxiety by which medical professionals see psychiatric patients in this context. As we have argued already 10 years ago (Pariante et al. 2002), withholding IFN-α inappropriately, especially from members of a stigmatized class, raises questions about fairness and discrimination.

The evidence

The aim of this editorial is to discuss the existing literature with regard to the administration of IFN-α therapy in patients with chronic hepatitis C and a current psychiatric illness. Studies were identified by using the PubMed database, cross-searching for ‘Interferon-α’, ‘psychiatric symptoms’ and ‘chronic hepatitis C’. Further references were obtained from bibliographies of the reviewed articles. Fourteen studies were considered eligible, and are summarized in Table 1, with details of the findings. Overall, most studies did not find a significantly higher risk of IFN-α-induced neuropsychiatric toxicity in patients with a psychiatric diagnosis, once the higher baseline psychopathology was taken into account. Interestingly, patients with severe mental illnesses, such as schizophrenia, seem also to be resilient during IFN-α. Furthermore, no higher suicidal risk was recorded in these patients. Of particular relevance, and consistently across all studies, is the fact that the rates of completion of therapy and sustained virological response are comparable between psychiatric and non-psychiatric patients.

Conclusions

Our analysis of the relatively scant literature highlights that patients with a psychiatric illness have rates of treatment adherence and sustained virological response similar to those of non-psychiatric patients. Moreover, the majority of the studies do not show a significantly higher neurotoxicity of IFN-α therapy in these patients; and even in those studies that find a greater incidence of psychiatric adverse events, psychiatric patients are able to successfully complete the therapy. The lack of an increased risk of suicide in psychiatric patients is also consistent with a recent review on this topic (Sockalingam et al. 2011), which also found that the evidence for an increased suicide risk during IFN-α is largely anecdotal. In most cases, a combination of psychotropic and psychosocial interventions can be used to both prevent worsening of existing symptoms and to manage patients who show a reactivation of psychiatric problems. In fact, there is reasonably good evidence in favour of use of antidepressants, for both prophylaxis and treatment of anxiety and depressive symptoms induced by IFN-α (Baraldi et al. 2012). In addition, the early involvement of a multidisciplinary therapeutic approach, such as the assessment and follow-up with liaison psychiatrists and psychologists (Neri et al. 2010), or an interdisciplinary nurse-managed treatment programme, can be used to support patients with pre-existent psychiatric problems undergoing IFN-α therapy (Gardenier et al. 2011). It should be noted that it is important not to underestimate the fact that patients with no psychiatric history have virtually the same risk of developing IFN-α-induced side-effects, and as
Acknowledgements

This paper received funding from The NIHR ‘Biomedical Research Centre for Mental Health’, Institute of Psychiatry and South London and Maudsley NHS Foundation Trust and the Commission of European Communities 7th Framework Programme Collaborative Project Grant Agreement no. 22963 (Mood Inflame).

Declaration of Interest

None.

References


